aldophosphamide

Aldophosphamide is a prodrug of cyclophosphamide, an alkylating agent used in chemotherapy. It is an orally administered form of cyclophosphamide, meaning it is taken by mouth. Once ingested, aldophosphamide is metabolized in the liver to its active form, cyclophosphamide, and other cytotoxic agents. Cyclophosphamide works by alkylating DNA, which disrupts DNA replication and transcription, ultimately leading to cell death, particularly in rapidly dividing cancer cells. Aldophosphamide has been used in the treatment of various cancers, including certain types of lymphomas, leukemias, and solid tumors. Its administration route can offer convenience for patients compared to intravenous chemotherapy. However, like other alkylating agents, aldophosphamide can cause side effects such as bone marrow suppression, nausea, vomiting, hair loss, and an increased risk of infection. It can also cause hemorrhagic cystitis, a bladder inflammation, which is managed by adequate hydration and sometimes the use of mesna. The specific dosage and treatment regimen depend on the type and stage of cancer being treated and the patient's overall health status. Research has explored its use in combination chemotherapy protocols to enhance efficacy and manage resistance.